DAFNA Capital Management LLC Acquires 467,836 Shares of COMPASS Pathways PLC Sponsored ADR $CMPS

Key Points

• DAFNA Capital Management LLC significantly increased its stake in COMPASS Pathways PLC by 192.4%, acquiring an additional 467,836 shares, bringing its total to 711,046 shares valued at $2,034,000.
• COMPASS Pathways reported a loss of ($0.38) EPS for the latest quarter, falling short of analysts' expectations of ($0.37) EPS.
• Analysts maintain a consensus rating of "Moderate Buy" for COMPASS Pathways, with target prices ranging from $6.00 to $15.00.

DAFNA Capital Management LLC boosted its stake in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 192.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 711,046 shares of the company's stock after buying an additional 467,836 shares during the period. DAFNA Capital Management LLC owned 0.77% of COMPASS Pathways worth $2,034,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Jane Street Group LLC lifted its holdings in COMPASS Pathways by 72.7% in the fourth quarter. Jane Street Group LLC now owns 51,815 shares of the company's stock worth $196,000 after buying an additional 21,815 shares during the period. Barclays PLC lifted its holdings in COMPASS Pathways by 2.1% in the fourth quarter. Barclays PLC now owns 419,194 shares of the company's stock worth $1,585,000 after buying an additional 8,718 shares during the period. GAMMA Investing LLC lifted its holdings in COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock worth $30,000 after buying an additional 5,003 shares during the period. Tang Capital Management LLC purchased a new stake in COMPASS Pathways in the fourth quarter worth about $3,780,000. Finally, Renaissance Technologies LLC lifted its holdings in COMPASS Pathways by 161.3% in the fourth quarter. Renaissance Technologies LLC now owns 212,700 shares of the company's stock worth $804,000 after buying an additional 131,300 shares during the period. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Up 4.2%

Shares of CMPS traded up $0.19 on Wednesday, hitting $4.71. 1,467,585 shares of the stock traded hands, compared to its average volume of 1,809,776. The company has a market capitalization of $451.88 million, a PE ratio of -2.56 and a beta of 2.17. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.82 and a current ratio of 8.82. The business has a 50 day simple moving average of $4.03 and a 200 day simple moving average of $3.85. COMPASS Pathways PLC Sponsored ADR has a one year low of $2.25 and a one year high of $7.53.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, equities analysts forecast that COMPASS Pathways PLC Sponsored ADR will post -2.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Evercore ISI restated an "in-line" rating and issued a $6.00 price objective (down from $11.00) on shares of COMPASS Pathways in a report on Monday, June 23rd. Cantor Fitzgerald reiterated an "overweight" rating and set a $12.00 target price on shares of COMPASS Pathways in a report on Tuesday, May 27th. HC Wainwright lowered their target price on shares of COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a report on Monday, August 4th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $15.00 target price on shares of COMPASS Pathways in a report on Friday, August 1st. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $16.29.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.